Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Financial Services

FIVE at FIVE AU: ASX mixed; RBA raises rates as expected

The local market ended the day lower, with the ASX 200 down 0.22%, after the RBA raised interest rates by a further 0.25% to 4.35%.

However, sector performance was split with the Tech sector up 1.67% while the interest rate-sensitive Financials sector was 1% lower.

Also feeling the RBA’s decision were real estate investment trusts (REITS) Scentre and Dexus which each dropped 2.3% before paring losses as the day went on.

Healthcare is up half a per cent despite being an interest rate-sensitive sector — Pro Medicus added 3% and Cochlear is up 1.3%.

RBA rate decision

As widely expected, the Reserve Bank of Australia today raised the cash rate by 0.25% to 4.35% — taking rates to their highest level in 12 years.

This is the RBA’s first rate rise since July and follows exceptionally high price growth in the September quarter, along with strong retail sales numbers. The RBA wants to return inflation to its target band of 2-3% by the end of 2025.

The Australian dollar lost a quarter of a cent in response, to US64.62¢, amid speculation that this won't be the central bank's last rise of the cycle.

The following is from the RBA’s statement:

“Inflation in Australia has passed its peak but is still too high and is proving more persistent than expected a few months ago. The latest reading on CPI inflation indicates that while goods price inflation has eased further, the prices of many services are continuing to rise briskly.

“While the central forecast is for CPI inflation to continue to decline, progress looks to be slower than earlier expected. CPI inflation is now expected to be around 3.5% by the end of 2024 and at the top of the target range of 2 to 3% by the end of 2025.

“The board judged an increase in interest rates was warranted today to be more assured that inflation would return to target in a reasonable timeframe.”

“Given that the economy is forecast to grow below trend, employment is expected to grow slower than the labour force and the unemployment rate is expected to rise gradually to around 4.25%. This is a more moderate increase than previously forecast.

"Wages growth has picked up over the past year but is still consistent with the inflation target, provided that productivity growth picks up.

“Whether further tightening of monetary policy is required to ensure that inflation returns to target in a reasonable timeframe will depend upon the data and the evolving assessment of risks.”

On this last point, NAB head of market economics Tapas Strickland noted, “[the RBA] softened its tightening bias from previous statements by adding the word ‘whether”.

State Street Global Markets head of APAC macro strategy Dwyfor Evans said:

“The recent higher-than-expected CPI prints clearly swayed the decision towards another hike. The focus on a 4-handle jobless rate also alludes to a continued strong labour market, which is important to the extent that it offsets fears of higher debt servicing costs given the propensity towards variable rates in Australia.

"It should also underpin consumer spending. A muted reaction, which reflects the bias towards expectations of a hike over recent days.”

Five at Five

Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has completed dosing of the first subjects at the highest concentration of 3,000 milligrams of RECCE® 327 at a faster infusion rate of 15 minutes, administered intravenously.

Read more

Stelar Metals ready for inaugural hard rock lithium drilling at Trident

Stelar Metals Ltd (ASX:SLB) is ready to kick off an inaugural hard rock lithium drilling program at its Trident Lithium Project near Broken Hill in New South Wales.

Read more

Aeris Resources hits up to 2.34% copper at Tritton’s Constellation deposit; confirms extension

Aeris Resources Ltd (ASX:AIS, OTC:ARSRF) has encountered high-grade copper in five of six extensional holes drilled at the Constellation deposit of the tenement package at Tritton operations in New South Wales.

Read more

OD6 Metals delivers “very positive” REE metallurgical results from Splinter Rock

OD6 Metals Ltd (ASX:OD6) has delivered “very positive” results from metallurgical tests on clay-hosted rare earth elements (REEs) at its Splinter Rock Project, northeast of Esperance in Western Australia.

Read more

Race Oncology to present “highly positive” AML clinical trial outcomes at American Society of Hematology annual conference

Race Oncology Ltd (ASX:RAC) has fielded “impressive” Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial.

Read more

On your six

OpenAI's DevDay heralds significant enhancements and reduced costs

During its first-ever developer conference, OpenAI has launched a suite of new models and developer tools, alongside notable reductions in pricing.

Read more

One to watch

Triangle Energy valued at 5.4 cents per share

Triangle Energy (Global) Ltd MD Conrad Todd speaks with Proactive following news the company and its 50-50 joint venture partner Athena Exploration Ltd have been offered five blocks in the West of Shetlands gas province which contains the Cragganmore gas field.

Watch more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK